Literature DB >> 705866

Further studies on the relationship of anti-Ena and anti-Wrb in warm autoimmune hemolytic anemia.

C A Bell, H Zwicker.   

Abstract

The red blood cell eluates of two patients with warm autoimmune hemolytic anemia (AIHA) were found to have anti-dl and anti-Wrb in a study of 150 individuals with positive AHG tests.7 In that series 39 per cent of AIHA cases had anti-Wrb as part of the autoantibody specificity. The eluates of these two patients were of further interest since they showed weaker reactions with En(a-) cells than with En(a+), Wr(a+b-) cells. Further absorption of the eluates confirmed a second component that reacted with the En(a+), Wr(b-) cells but not the En(a-) cell, interpreted as autoanti-Ena. In one of the cases anti-Ena was recovered from the En(a-) absorbing cell although these cells were not agglutinated by the autoantibody. This effect was not due to polyagglutinability, the Matuhasi-Ogata phenomenon or the decreased sialic acid content of the En(a-) red blood cell membranes and remains unexplained.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 705866     DOI: 10.1046/j.1537-2995.1978.18579036389.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Human and murine splenic neutrophils are potent phagocytes of IgG-opsonized red blood cells.

Authors:  Sanne M Meinderts; Per-Arne Oldenborg; Boukje M Beuger; Thomas R L Klei; Johanna Johansson; Taco W Kuijpers; Takashi Matozaki; Elise J Huisman; Masja de Haas; Timo K van den Berg; Robin van Bruggen
Journal:  Blood Adv       Date:  2017-05-26

2.  Erythrocyte membrane proteins reactive with human (warm-reacting) anti-red cell autoantibodies.

Authors:  J P Leddy; J L Falany; G E Kissel; S T Passador; S I Rosenfeld
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 3.  The Clinical Pictures of Autoimmune Hemolytic Anemia.

Authors:  Charles H Packman
Journal:  Transfus Med Hemother       Date:  2015-09-11       Impact factor: 3.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.